https://ymaho.com/crispr-therapy-hae-phase-3-data-from-intellia-at-eaaci-2026
Intellia presented the long-awaited results of phase 3 of CRISPR therapy lonvoguran ziclumeran for hereditary angioedema. Reduction of attacks by 87%, 62% of patients without therapy. Learn more.